Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron”

Oh man, you cognize what? I should person pulled the trigger connected Regeneron erstwhile I sat down with them astatine the JPMorgan conference. I realized that the Charitable Trust should person owned it. It would’ve a overmuch better, truly overmuch amended cause banal than the others that we have, with the objection of Eli Lilly.

Stock marketplace data. Photo by Photo by Alesia Kozik

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for oculus conditions, immune disorders, cancer, cardiovascular issues, infections, and uncommon diseases. During the December 1, 2025, episode, a caller highlighted that the banal is up importantly from its summertime 2025 lows and asked Cramer if it tin proceed its momentum. In response, the Mad Money big stated:

Yes, down 30 today… Well, it’s a $750 stock. Now, fto maine conscionable archer you something. Regeneron’s determination has been quiet, but Len Schleifer has been telling me, enactment focused connected what they’re doing. They’re doing a batch of bully stuff. I mislaid show of it. I shouldn’t have. This 1 and Amgen fuss me. They happened without me, and that was my bad, and I’m gladsome you brought it to our attention.

While we admit the imaginable of REGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.